Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Parkinson Disease 4, Autosomal Dominant Lewy Body 25Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 20Melanoma 19Neoplasm Metastasis 18Neoplasms 16Endometrial Neoplasms 14Colorectal Neoplasms 14Breast Neoplasms 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 11Head and Neck Neoplasms 9Carcinoma, Renal Cell 8Pancreatic Neoplasms 7Carcinoma, Transitional Cell 7Urinary Bladder Neoplasms 6Recurrence 5Lymphoma 5Hodgkin Disease 5Esophageal Neoplasms 4Carcinoma 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Prostatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

Radiotherapy 5Oxaliplatin 5Nivolumab 5Fluorouracil 5Cetuximab 5Leucovorin 4Magnetic Resonance Spectroscopy 3Bevacizumab 3sintilimab 2pembrolizumab 2fludarabine 2encorafenib 2aldesleukin 2Tomography, X-Ray Computed 2Specimen Handling 2Pemetrexed 2Magnetic Resonance Imaging 2Irinotecan 2Gemcitabine 2Folfox protocol 2Electrocardiography 2Drug Therapy 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Biopsy 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × pembrolizumab × 30 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Pfizer

Phase 1 Terminated
30 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡